Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05665530 · ClinicalTrials.gov registry record · Phase 1
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
A Phase 1 study, sponsored by Prelude Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT05665530 is a Phase 1 study that has completed, run by Prelude Therapeutics. The registered enrollment target is 86 participants.
The verdict
NCT05665530, a Phase 1 study, has completed, sponsored by Prelude Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib or venetoclax.
Interventions
- DRUG Zanubrutinib
- DRUG Venetoclax
- DRUG PRT2527
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2023-09-12 |
| Est. Completion | 2026-01-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05665530
The ClinicalTrials.gov registry entry for NCT05665530 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zanubrutinib is the first listed.
NCT05665530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05665530 about?
NCT05665530 is a clinical study titled "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies". This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose ...
What is the current status of trial NCT05665530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2023-09-12. Estimated completion is 2026-01-21.
What interventions are being tested in trial NCT05665530?
The interventions under investigation include: Zanubrutinib (DRUG), Venetoclax (DRUG), PRT2527 (DRUG).
Who is sponsoring clinical trial NCT05665530?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.